Shilpa Medicare Limited — Updates, 22-11-2025: General Updates
22-11-2025 | 11:55 am
22-11-2025 | 11:55 am
Shilpa Medicare's Jadcherla Unit IV USFDA inspection concluded with 8 observations; none were repeats. US sales from this unit are less than 1% of total business for H1 FY26, suggesting minimal immediate revenue risk. The company plans to respond.
No comments yet. Be the first to comment!
